相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma
Ali McBride et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia
Ali McBride et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz
Ali McBride et al.
FUTURE ONCOLOGY (2017)
Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia
Ali McBride et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012
Eric Tai et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice
Jeffrey Crawford et al.
Journal of the National Comprehensive Cancer Network (2017)
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
Pere Gascon et al.
SUPPORTIVE CARE IN CANCER (2016)
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
M. Aapro et al.
ANNALS OF ONCOLOGY (2016)
Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer
Nadia Harbeck et al.
FUTURE ONCOLOGY (2016)
A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial
Kimberly Blackwell et al.
ONCOLOGIST (2016)
Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study
Diana Sun et al.
CLINICAL THERAPEUTICS (2015)
Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review
Xiao Jun Wang et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries
Ivo Abraham et al.
FUTURE ONCOLOGY (2014)
G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use
Gisoo Barnes et al.
CANCER MEDICINE (2014)
Costs Associated with Febrile Neutropenia in the US
Shannon L. Michels et al.
PHARMACOECONOMICS (2012)
Pharmacoeconomics of the Myeloid Growth Factors A Critical and Systematic Review
Bradford R. Hirsch et al.
PHARMACOECONOMICS (2012)
Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer
Matti Aapro et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia
Matti Aapro et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2011)
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
NM Kuderer et al.
CANCER (2006)
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
V Caggiano et al.
CANCER (2005)
分享论文
